MS21

Item no.	HY-141807-1ea
Manufacturer	MedChem Express
CASRN	2376137-05-0
Amount	1 ea
Quantity options	100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.88
Citations	[1]Xu J, et al. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discov. 2021 Jul 23.
Smiles	NC1(CCN(C2=NC=NC3=C2C=CN3)CC1)C(N[C@@H](CCN4CCN(C(CCCCCCCCCC(N[C@@H](C(C)(C)C)C(N5C[C@H](O)C[C@H]5C(NCC6=CC=C(C7=C(C)N=CS7)C=C6)=O)=O)=O)=O)CC4)C8=CC=C(Cl)C=C8)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Akt; PROTACs
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	1107.84
Product Description	MS21 is an effective AKT PROTAC degrader. MS21 can inhibit mutations in the PI3K/PTEN pathway, suppress the proliferation and induce cell cycle arrest of tumor cells. MS21 has anti-tumor activity. (Pink: AKT ligand-2 (HY-48682); Black: Linker (HY-W014125); Blue: (S, R, S)-AHPC (HY-125845))[1].
Manufacturer - Research Area	Cancer
Solubility	Methanol: 95 mg/mL (ultrasonic)
Manufacturer - Pathway	PI3K/Akt/mTOR; PROTAC
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-141807-1ea-safety-datasheet.pdf